Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 2Breast 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Colorectal Neoplasms 2Colonic Neoplasms 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Drug Evaluation × Gastrointestinal × Clear all
NCT05189171 2024-06-28

MODEL-CRC

Xilis, Inc.

Completed
46 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT00582660 2017-06-15

UAB0040

University of Alabama at Birmingham

Phase 2 Completed
40 enrolled 7 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡